Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains

1 Apr 2007

Abstract excerpt

Cancer is a highly heterogeneous disease in terms of the genetic profile and the response to therapeutics. An early identification of a genomic marker in drug discovery may help select patients that would respond to treatment in clinical trials. Here we suggest coupling compound screening with comparative genomic hybridization analysis of the model systems for early discovery of genomic biomarkers. A Bcl-2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glycosylation and Glycoproteins Research
Share to Lung Cancer Research Studies
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17426248
DOI: 10.1158/1541-7786.mcr-06-0367

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal GainsPMID 17426248Read ↗

Functional Genomics Identifies ABCC3 as a Mediator of Taxane Resistance in HER2-Amplified Breast CancerSemantic proximity Read ↗

Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung CancerSemantic proximity Read ↗

Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell LinesSemantic proximity Read ↗

A framework for identification of actionable cancer genome dependencies in small cell lung cancerSemantic proximity Read ↗

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.Semantic proximity Read ↗

Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737Semantic proximity Read ↗

Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.Semantic proximity Read ↗

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA ExpressionSemantic proximity Read ↗

Systems therapeutics analyses identify genomic signatures defining responsiveness to allopurinol and combination therapy for lung cancerSemantic proximity Read ↗

Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomasSemantic proximity Read ↗

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerSemantic proximity Read ↗

Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.